Search

Author/Creator Chen, C.

1. 195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. (December 2022)

Authors:
Csiki, I.; Glenn, J.; Boccia, R.; Chen, C.; Gordon, M.; Misleh, J.; Powderly, J.; Wainberg, Z.A.; Spira, A.; Klumpp, K.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. [BP.02.02] RATE OF MORNING BLOOD PRESSURE SURGE IS A BETTER PREDICTOR THAN AMPLITUDE FOR 20-YEAR ALL-CAUSE AND CARDIOVASCULAR MORTALITIES: RESULTS OF A COMMUNITY-BASED STUDY. (September 2017)

Authors:
Cheng, H.; Sung, S.; Wu, C.; Lee, J.; Kario, K.; Chiang, C.; Hsu, P.; Chuang, S.; Wang, W.; Lakatta, E.; Yin, F.; Chou, P.; Chen, C.
Journal:
Journal of hypertension
Issue:
Volume 35(2017)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. A bacterial‐biofilm‐induced oral osteolytic infection can be successfully treated by immuno‐targeting an extracellular nucleoid‐associated protein. (5th April 2016)

Authors:
Freire, M.O.; Devaraj, A.; Young, A.; Navarro, J.B.; Downey, J.S.; Chen, C.; Bakaletz, L.O.; Zadeh, H.H.; Goodman, S.D.
Journal:
Molecular oral microbiology
Issue:
Volume 32:Number 1(2017)
Page Start:
74
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗